KLRK1 and prostate carcinoma: Studies have demonstrated that prostate cancer cell-derived TDEVs express NKG2D ligands on their surface, which downregulate NKG2D expression on NK cells and CD8+ T cells, thereby impairing their cytotoxic functions (Lundholm et al., 2014).